Group 1 - The core transaction involves MicroPort Cardio Flow CRM Limited acquiring CRM Cayman through a merger agreement, with CRM Cayman becoming a wholly-owned subsidiary of MicroPort Cardio Flow upon completion [1][2] - The merger will involve the issuance of new shares at a price of HKD 1.35 per share to CRM Cayman shareholders, with a pre-transaction equity value of CRM Cayman estimated at USD 680 million [1][2] - The merger is strategically aligned with MicroPort Cardio Flow's business development, aiming to establish a global cardiac product platform and enhance its product offerings and capabilities in structural heart disease and arrhythmia management [2] Group 2 - CRM Cayman and its subsidiaries focus on arrhythmia management solutions, providing devices to monitor heart conditions and deliver treatments [2] - MicroPort Cardio Flow specializes in innovative transcatheter solutions for structural heart disease, with products including valve products and left atrial appendage occluders [2] - The merger is expected to create complementary synergies that will diversify and expand MicroPort Cardio Flow's existing business, particularly in research and development, manufacturing, distribution channels, and market expansion [2]
微创医疗(00853.HK)拟进行心律管理业务策略性重组而订立合并协议